Integration of Machine Learning and Mechanistic Models Accurately Predicts Variation in Cell Density of Glioblastoma Using Multiparametric MRI by Gaw, Nathan et al.
Barrow Neurological Institute at St. Joseph's Hospital and Medical Center 
Barrow - St. Joseph's Scholarly Commons 
Neurosurgery 
2019 
Integration of Machine Learning and Mechanistic Models 
Accurately Predicts Variation in Cell Density of Glioblastoma 
Using Multiparametric MRI 
Nathan Gaw 
Andrea Hawkins-Daarud 
Leland S. Hu 
Hyunsoo Yoon 
Lujia Wang 
See next page for additional authors 
Follow this and additional works at: https://scholar.barrowneuro.org/neurosurgery 
Recommended Citation 
Gaw, Nathan; Hawkins-Daarud, Andrea; Hu, Leland S.; Yoon, Hyunsoo; Wang, Lujia; Xu, Yanzhe; Jackson, 
Pamela R.; Singleton, Kyle W.; Baxter, Leslie C.; Eschbacher, Jennifer; Gonzales, Ashlyn; Nespodzany, 
Ashley; Smith, Kris A.; Nakaji, Peter; Mitchell, J. Ross; Wu, Teresa; Swanson, Kristin R.; and Li, Jing, 
"Integration of Machine Learning and Mechanistic Models Accurately Predicts Variation in Cell Density of 
Glioblastoma Using Multiparametric MRI" (2019). Neurosurgery. 216. 
https://scholar.barrowneuro.org/neurosurgery/216 
This Article is brought to you for free and open access by Barrow - St. Joseph's Scholarly Commons. It has been 
accepted for inclusion in Neurosurgery by an authorized administrator of Barrow - St. Joseph's Scholarly 
Commons. For more information, please contact molly.harrington@dignityhealth.org. 
Authors 
Nathan Gaw, Andrea Hawkins-Daarud, Leland S. Hu, Hyunsoo Yoon, Lujia Wang, Yanzhe Xu, Pamela R. 
Jackson, Kyle W. Singleton, Leslie C. Baxter, Jennifer Eschbacher, Ashlyn Gonzales, Ashley Nespodzany, 
Kris A. Smith, Peter Nakaji, J. Ross Mitchell, Teresa Wu, Kristin R. Swanson, and Jing Li 
This article is available at Barrow - St. Joseph's Scholarly Commons: https://scholar.barrowneuro.org/neurosurgery/
216 
1Scientific RepoRts |         (2019) 9:10063  | https://doi.org/10.1038/s41598-019-46296-4
www.nature.com/scientificreports
Integration of machine learning 
and mechanistic models accurately 
predicts variation in cell density of 
glioblastoma using multiparametric 
MRI
Nathan Gaw1, Andrea Hawkins-Daarud  2, Leland s. Hu3, Hyunsoo Yoon  1, 
Lujia Wang1, Yanzhe Xu  1, pamela R. Jackson2, Kyle W. singleton  2, Leslie C. Baxter3, 
Jennifer eschbacher4, Ashlyn Gonzales3, Ashley Nespodzany3, Kris smith  5, peter Nakaji5, 
J. Ross Mitchell  6, teresa Wu1, Kristin R. swanson2,7 & Jing Li1
Glioblastoma (GBM) is a heterogeneous and lethal brain cancer. these tumors are followed using 
magnetic resonance imaging (MRI), which is unable to precisely identify tumor cell invasion, impairing 
effective surgery and radiation planning. We present a novel hybrid model, based on multiparametric 
intensities, which combines machine learning (ML) with a mechanistic model of tumor growth to 
provide spatially resolved tumor cell density predictions. the ML component is an imaging data-driven 
graph-based semi-supervised learning model and we use the proliferation-Invasion (pI) mechanistic 
tumor growth model. We thus refer to the hybrid model as the ML-pI model. the hybrid model was 
trained using 82 image-localized biopsies from 18 primary GBM patients with pre-operative MRI 
using a leave-one-patient-out cross validation framework. A Relief algorithm was developed to 
quantify relative contributions from the data sources. The ML-PI model statistically significantly 
outperformed (p < 0.001) both individual models, ML and PI, achieving a mean absolute predicted error 
(MAPE) of 0.106 ± 0.125 versus 0.199 ± 0.186 (ML) and 0.227 ± 0.215 (PI), respectively. Associated 
Pearson correlation coefficients for ML-PI, ML, and PI were 0.838, 0.518, and 0.437, respectively. The 
Relief algorithm showed the pI model had the greatest contribution to the result, emphasizing the 
importance of the hybrid model in achieving the high accuracy.
Gadolinium contrast-enhanced T1-weighted (T1Gd) MRI serves as the clinical standard for guiding surgical 
resection and radiation therapy in glioblastoma (GBM), an aggressive primary brain tumor. While the con-
trast enhancement on a T1Gd MRI highlights the areas of a disrupted blood-brain-barrier and not the tumor 
cells directly1, this physiological disturbance does generally correlate with regions of higher tumor cell density2. 
Unfortunately, this rule-of-thumb correlation is not accurate enough to ensure that spatially targeted therapies, 
guided by the T1Gd, will provide optimal outcomes. More globally, this non-specificity impacts the ability to 
interpret how a given tumor responded to therapy, causing doubt in therapeutic decisions throughout the course 
of the disease1,3,4. Indeed, a wealth of evidence has shown that MRI enhancement underestimates true tumor 
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burden, due to poor delineation of invasive tumor regions with intact BBB5–8, and that resection (better able to 
target the bulk of the tumor) results in an increase in overall survival9. These non-enhancing tumor populations 
can represent a substantial proportion of overall disease burden7,9, yet typically remain unresected (by surgery) 
and undertreated (by radiation), thereby leading to universal recurrence and poor survival.
There have been a number of attempts to use other types of clinical imaging to directly show the tumor inva-
sion. Perhaps the most common is the Apparent Diffusion Coefficient (ADC) map, generated from diffusion 
MRI, which has previously been shown to inversely correlate with cell density10–12. However, this relationship 
to overall cell density is not easily converted to tumor cell density only, which is the primary variable of interest 
in the invasive rim of the tumor. Unfortunately, this uncertain area is the main region of interest for expanding 
spatially targeted therapies. Radio-labeled tracers used with positron emission tomography (PET) can also high-
light actively proliferating regions within the brain13–15. While promising, the resolution of PET scans are not 
nearly as accurate for surgical planning as MRI and these scans are also more difficult to obtain due to the use of 
non-standard tracers with shorter half-lives and the need of a PET scanner16. In this paper, we present a hybrid 
method, consisting of machine learning and mechanistic model components, for predicting specifically the tumor 
cell density based on multi-parametric MRI.
Machine learning (ML) approaches have been gaining popularity in trying to elucidate tumor characteris-
tics using radiological features17–22. Due to the limited data regarding spatial localization of tissue specimens 
(biopsies) from tumors typically collected, previous radiomics models have primarily aimed at categorizing the 
entirety of a tumor according to a given label derived from a single tissue sample, i.e. IDH1mut status, MGMT 
methylation status, or Verhaak tumor type17,18,23. We have made use of a unique data set consisting of multiple 
image-localized biopsies from 18 patients to enable spatially heterogeneous predictions of tumor cell density 
throughout an individual tumor.
Our approach is further unique in that it brings together the strengths of both machine learning (ML) and 
mechanistic models (MM). ML is very powerful in that it lets the data completely determine the relationship 
between the medical images and the variable being predicted. However, this can also be a weakness in that if there 
is not enough data to fully capture the uncertainties in a given relationship, ML is very susceptible to overfitting. 
MM can help fill in these gaps by encapsulating known relationships and feeding this supplemental knowledge to 
the ML model. For this purpose, we make use of the Proliferation-Invasion (PI) model of glioma growth, a model 
that can be made patient-specific and has been shown to have significance in predicting radiation sensitivity, 
benefit from resection, therapeutic response, and overall survival24–29. We thus refer to our hybrid model as the 
ML-PI model.
Following this introduction, we provide a brief background on the ML algorithms used and the PI model. We 
then present our methods including a succinct overview of how we combine the ML and PI models to form a 
single hybrid model. We then show the accuracy of our hybrid model is better than when compared to predictions 
from ML or PI alone. We also determine the significant contributing features to the ML-PI model demonstrating 
that the hybrid approach is critical to the success of this model.
Methods
patient recruitment. Patients were recruited with clinically suspected GBM undergoing preoperative stere-
otactic MRI for first-line surgical resection prior to any treatment, as per the institutional review board approved 
protocol “Improving Diagnostic Accuracy in Brain Patients Using Perfusion MRI” at Barrow Neurological 
Institute (BNI). All patients provided written, informed consent prior to enrollment following the protocol proce-
dures approved by BNI’s IRB. Data was collected and all protocol procedures were carried out in accordance with 
relevant guidelines and regulations. The patient cohort presented here has also been described in previous stud-
ies19,20. 82 biopsy samples were collected from 18 GBM patients, with each patient having 2–14 biopsy samples.
surgical biopsy. Pre-operative conventional MRI, including T1-Weighted gadolinium contrast-enhanced 
(T1Gd) and T2-Weighted sequences (T2W), was used to guide biopsy selection. Each neurosurgeon collected an 
average of 5–6 tissue specimens from each tumor by using stereotactic surgical localization, following the smallest 
possible diameter craniotomies to minimize brain shift. Specimens were collected from both enhancing mass (as 
seen on T1Gd) and non-enhancing brain around tumor (BAT), as seen on T2W, for each tumor. The neurosur-
geons recorded biopsy locations via screen capture to allow subsequent coregistration with multiparametric MRI 
datasets. The biopsy tissue specimens were reviewed blinded to diagnosis by a neuropathologist and assessed for 
tumor content. Taking into account all visible cells (neurons, inflammatory cells, reactive glia, tumor cells, etc.), 
the percent tumor nuclei were estimated by a board-certified neuropathologist. Additional details of methods for 
surgical biopsy and pathological density measurement can be found in19.
Multiparametric MRI and RoI segmentation. We included six multiparametric images in the present 
study, including T1Gd, T2W, dynamic contrast enhancement (EPI + C), mean diffusivity (MD), fractional aniso-
tropy (FA), and relative cerebral blood volume (rCBV) (detailed MRI protocols and image co-registration can be 
found in19 and the Supplementary Information). The T2W ROI, region encompassing the abnormality on both 
the T2W and T1Gd images, of each tumor was manually segmented by a board-certified neuroradiologist as the 
target region for predictions.
pI density estimation. The proliferation-invasion (PI) model aims to capture the most basic understanding 
of what cancer is: cells that grow uncontrollably and invade surrounding tissue. Mathematically, the PI model is 
written as follows:
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where c(x, t) is the tumor cell density, D(x) is the net rate of diffusion taken to be piecewise constant with different 
values in gray and white matter, ρ is the net rate of proliferation and K is the cell carrying capacity. This model 
has been used to predict prognosis30, radiation sensitivity27, benefit from resection9, and IDH1 mutation status31. 
Additionally, this model was used to create untreated virtual controls for use in defining response metrics that are 
more prognostically significant than those currently in use28,32.
Using the T1Gd and T2W images of each patient as input, a D and ρ value were computed for each patient33; 
these values were then used to produce a voxel-wise density estimation co-registered to the other images through 
the algorithm outlined in34.
Image feature computation. An 8 × 8 voxel box was placed at the location of co-registered images and the 
PI-density map that corresponds to each biopsy sample. The average gray-level intensity over the 64 voxels within 
the box was computed for each image sequence as was the average PI-predicted tumor cell density. An additional 
slice of the MRI sequences was chosen for each patient from which we acquired unlabeled samples. The slice was 
selected such that the cross-section included a balanced amount of enhancing mass and non-enhancing BAT. 
8 × 8 voxel boxes were placed one pixel apart on the T2W ROI of the chosen slice, and the average gray-level 
intensity and PI-predicted tumor cell density were calculated for each of these unlabeled samples, analogous to 
the labeled samples.
Data augmentation by synthetic biopsies. As tissue is primarily acquired from regions suspected to be 
tumorous, the labeled samples were biased towards higher tumor cell densities (shown in Fig S1(a)). To provide 
a balanced dataset for ML-PI model training, synthetic biopsies, taken from regions expected to be low in tumor 
cell density, were identified for each patient (if necessary) to be included among the labeled data points. A total 
of 39 synthetic biopsy samples were added with each patient having 0–6 samples. Synthetic biopsies were treated 
in the same manner as the original labeled data for model training purposes. It is important to note that the syn-
thetic biopsies were only used in model training, and not in validation of the model performance.
Hybrid model development. Our hybrid model is comprised of two parts a semi-supervised learning 
approach and a mechanistic model. The general overview of the model is shown in Fig. 1.
Figure 1. Workflow of building ML-PI and using the model to generate a predicted cell density map for the 
T2W ROI of each tumor/patient. Image-localized biopsies and multiparametric MRIs were collected for each 
patient in our study. The images were all co-registered and the voxel corresponding to the biopsy location 
was identified. PI-model Volumes of abnormality observed on T1Gd and T2 images were calculated via 
segmentation and were used to tune the PI model for each patient to provide a PI prediction of the tumor cell 
density. Labeled Samples For each image-localized biopsy, the mean intensity was calculated for each image 
sequence and PI cell density prediction corresponding to an 8 × 8 voxel window centered at the biopsy location. 
Unlabeled Samples A representative slice from the MRIs was selected. This slice was chosen such that it did not 
contain an image-localized biopsy location. The region of interest was segmented by a neuro-radiologist (LH) 
on this slice and a mean intensity from each MRI sequence and PI cell density was calculated from an 8 × 8 
voxel window corresponding to every voxel contained within the region of interest. Hybrid Model These mean 
intensities from both labeled and unlabeled samples were used in the training of our hybrid ML-PI model. 
Validation tests were done using labeled sample data only.
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Semi-supervised learning (SSL). SSL has been widely used in applications in which labeled data are scarce but 
unlabeled data are available in large quantity, such as in our case in which there are very few biopsy-associated 
MRI voxels but numerous non-biopsy associated voxels. There are many types of SSL algorithms, but here we 
utilize a graph-based algorithm as presented in35 as our baseline model because of its proven high accuracy and 
efficiency in various applications, as well as its inductive learning ability that allows the trained model to be used 
to predict new patients. The core idea is to construct a graph with vertices being labeled and unlabeled samples in 
a training set and edges weighted by vertex proximity in the feature space.
Mechanistic Proliferation-Invasion (PI) model for patient-specific tumor cell density estimation. The vast major-
ity of the clinically relevant PI literature, model discussed above, focuses on the intuition derived from the 
patient-specific parameter values (D and ρ), i.e. the gross tumor growth profile, rather than a voxel by voxel cell 
density prediction. This is exactly because the PI model smooths local regional cell density differences on this 
scale. The use of the PI model cell densities in the hybrid model presented here is for a similar purpose: these 
predictions provide an insight into the expected overall pattern but need to be augmented by more sophisticated 
data-driven ML methods to achieve local accuracy. That is, the biological insights provided by the PI model pro-
vide a means to regularize the ML models for tumor cell invasion.
Hybrid Model. The key concept in the creation of the hybrid ML-PI model is to incorporate PI-estimated 
regional cell density and imaging information from unbiopsied regions into a graph-based SSL. Briefly, it can be 
written mathematically as the solution to the following minimization problem:
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This model is an expansion from a typical supervised model, which would be composed of just the first two 
terms in eq. (1), by the third term incorporating the PI predictions and imaging information from unbiopsied 
regions. In this model, L is the number of biopsy samples in a training dataset. yl is the pathologically measured 
tumor cell density for the l-th sample. xl = (zl, PIl), where zl contains gray-level intensity of each MRI sequence 
and PIl is the PI predicted cell density (both zl and PIl contain values averaged over the 8 × 8 voxel box placed at 
the l-th biopsy sample location). f(xl) is a predictive function for cell density. K
2|| ⋅ ||  is a norm on the reproducing 
kernel Hilbert space K . γA and γl are tuning parameters. f contains predictive density for each labeled and unla-
beled sample, i.e., given U is the number of unlabeled samples, f = (f(x1), …, f(xL), f(xL+1), …, f(xL+U))T. Ω is a 
Laplacian matrix encoding the graph by holding the edge weight and connection information. Finally, wij are the 
edge weights between vertices vi and vj, i, j = 1, …, L + U, of the graph capturing the relative difference in MRI 
features (wij,z) and PI predictions (wij,PI) can be computed using a product of two Gaussian functions, i.e.,
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It can be shown, see Supplementary Information, that a solution to (1) exists and that it takes the form:
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width of the basis function. The αi’s can be determined analytically in terms of the three tuning parameters γA, γl, 
and η. This model and solution are discussed with much more detail and rigor in the Supplementary Material.
parameter tuning. The hybrid ML-PI model includes three parameters that need to be tuned: γA, which 
weights the kernel smoother, γI, which weights the influence of unbiopsied regions and PI cell density prediction, 
and η, which is the width of the radial basis function kernel. The tuning ranges used were γI, γA ∈ {10−10, …, 104}; 
η ∈ {10−1, …, 102}. We compared two tuning strategies: patient-specific tuning and uniform tuning. The former 
finds the optimal tuning parameters for each patient while the latter assumes the same optimal tuning parameters 
across all patients.
Patient-Specific Tuning. To individualize an ML-PI model for each patient, we utilized only the training samples 
from the other patients in the first term of Eq. (1). No real or synthetic biopsy samples from the target patient were 
used in training in order to avoid overfitting. Then, the trained model was used to predict the real biopsy samples 
of the target patient. The optimal tuning parameters were those that minimized the mean absolute prediction 
error (MAPE) of the real biopsies on the target patient. Selected parameters are given in Table S2.
Uniform Tuning. To find a single ML-PI model that could be applied to any patient, we looked for a single set of 
tuning parameters that minimized the MAPE across all patients. Thus, all patient samples were utilized in the first 
term of Eq. (1). Selected parameters are given in Table S3.
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Feature contribution analysis for ML-pI. To quantify the contribution of each feature, i.e. the mean 
image intensities and PI-estimated density, to the prediction made by ML-PI, we developed a modified Relief 
algorithm36, which we call “Relief-ML-PI”. This algorithm is run as a post-processing step and results in a score 
for each imaging feature x, s(x), that represents the contribution of x. Given i and ir are samples in the training 
data set where ir is the rth nearest neighbor of i on the graph G, yˆi and yˆir are the predicted cell density of the two 
samples by ML-PI, yˆi and yˆir which correspond to feature measurements of x, xi and xir, we define s(x) as the dif-ference between two probabilities, i.e.,
ˆ ˆ
ˆ ˆ
( )
( )
s x P x x are different y y are different
P x x are different y y are similiar
( ) and and
and and (4)
i i i i
i i i i
r r
r r
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The first term represents the probability that feature x is able to separate samples with different prediction 
values, while the second term represents the probability that x separates samples with similar prediction values. 
The larger the first probability and/or the smaller the second, the higher the s(x). Further discussion of this metric 
and our algorithm for computing the values is provided in the supplement.
Results
Difference in accuracy for different tuning strategies. In order to determine the degree to which 
patient difference would influence the optimal tuning parameters of ML-PI, we first compared the accuracy of 
ML-PI between the two training strategies, patient-specific and uniform. Table 1 shows the comparison result 
using two metrics: MAPE and Pearson correlation between the predicted and pathological cell density meas-
urements. Both metrics allowed for a 5% error margin in the pathological measurement, i.e., if a predicted value 
is within ±5% of the pathological measurement, the prediction is considered correct (i.e., with zero prediction 
error). A MAPE of 0.106 means that if the pathologically measured density of a sample is b% (0 ≤ b ≤ 100), the 
predicted density by ML-PI deviates from b% by 10.6% on average. From Table 1 it is clear to see that patient-spe-
cific tuning has a significantly better accuracy than uniform tuning in terms of both a smaller MAPE (p < 0.0025) 
and a higher Pearson correlation (p < 0.001).
All Samples BAT Samples Only
MAPE ± SD
Pearson 
Correlation MAPE ± SD
Pearson 
Correlation
Patient-Specific ML-PI 0.106 ± 0.125 0.838 0.132 ± 0.118 0.820
Uniform ML-PI 0.176 ± 0.177 0.588 0.195 ± 0.179 0.504
PI 0.227 ± 0.215 0.437 0.204 ± 0.204 0.416
ML 0.199 ± 0.186 0.518 0.233 ± 0.209 0.208
Table 1. Prediction accuracy of all models: Patient-specific ML-PI, Uniform ML-PI, PI only, and ML only. 
Accuracy is considered for both cases of utilizing all samples or samples from the BAT only.
Figure 2. Illustrative spatial prediction maps resulting from three different models for two different patients. 
Red to blue colors represent 100–0% density. Models presented are the patient-specific hybrid ML-PI, the PI, 
and the ML. The weight given to the third term in Eq. (1) helps the hybrid model prediction to keep the general 
shape of the PI prediction and use information from unbiopsied regions, while the first term encourages 
accuracy in the prediction of biopsy samples and the second term promotes model stability/generalizability.
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Hybrid model more accurate than individual models. The output from each of these models is a spa-
tially varying map of tumor cell density. Figure 2 provides illustrative examples of these for two patients. In Fig. 2, 
one can also see the effect on the prediction of combining the ML and PI models. It can be observed that the map 
by ML-PI generally conforms to the global shape of the PI map, but regional variations are allowed making its 
predictions more accurate than using PI and ML alone.
All Samples. We wanted to test the performance of ML-PI against PI and ML used alone. The ML model is a 
supervised learning model that takes the same form of ML-PI except with γI = 0, i.e., a model that does not lever-
age unlabeled data. Table 1 shows the MAPE and Pearson correlation and Fig. 3 shows the plots of the predicted 
vs. pathological tumor cell density for each model. Compared with the patient-specific ML-PI, PI and ML alone 
had a significantly worse accuracy in terms of both MAPE and Pearson correlation (p < 0.001 in all comparisons). 
Also, we present the patient-wise MAPEs of ML-PI, PI, and ML in Table S1, found in the Supporting Information, 
to allow for comparison on the patient-level. ML-PI was able to predict more accurately than ML and PI in 17 out 
of 18 patients.
Brain Around Tumor (BAT) Samples Only. The BAT region is clinically interesting as that is most challenging 
to interpret through the obscured lens of MRI. Therefore, we further compared the performance of ML-PI, PI, 
and ML on predicting the tumor density of samples in the BAT. Out of the 82 total samples, 33 are in this area. 
The right two columns of Table 1 show the MAPE and Pearson correlation of each model and Fig. 3 additionally 
shows the predicted vs. pathological tumor cell density of the 33 samples for each of the three models. One can 
see from both Table 1 and Fig. 3 that ML-PI significantly outperforms PI and ML within the BAT region in all the 
comparisons (p < 0.05).
Importance of Individual tuning parameters. We further investigated which of the three tuning param-
eters have a greater effect on model accuracy when allowed to be patient-specific. To achieve this purpose, we 
added a third tuning strategy, partially-uniform tuning, in which two of the three tuning parameters were kept 
the same across all patients while the remaining one was allowed to vary from patient to patient. This results in 
three models corresponding to γA, γI, or η as the parameter allowed to be patient-specific, respectively. Table 2 
shows the performance of the three models. Compared with the result of uniform tuning in Table 1, we see 
patient-specific tuning of γA resulted in a significantly improved MAPE and Pearson correlation (p = 0.023 and 
Figure 3. Prediction versus truth correlation plots. Here we show the scatter plots of prediction vs truth 
coming from three models, patient-specific ML-PI (top row), PI only (middle row) and ML only (bottom 
row). The plots in the left column include all 82 biopsy samples and the ML-PI and ML models were trained 
using all available samples. The plots in the right column include the prediction on only the 33 biopsy samples 
originating in the non-enhancing (BAT) region. The r value denotes the Pearson correlation coefficient. 
Correlation values for both columns are the highest for the patient-specific ML-PI model and significantly 
better than those corresponding to PI and ML alone (in both all samples and samples from BAT only). The 
p-values in the ML and PI plots correspond to comparing the model’s correlation to the correlation of the 
corresponding patient-specific ML-PI.
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0.011). While patient-specific tuning of either η (p = 0.087 and 0.17)or γI (p = 0.22 and 0.35) alone does not result 
in a significantly improved MAPE and Pearson correlation. Selected tuning parameters are listed in Table S4.
Contributions from MRI sequences and pI. Using Relief-ML-PI, we can compute a contribution score 
for each image feature (one feature per MRI sequence) and PI from the ML-PI model specific to each patient. 
To identify the contributions aggregated over all the patients, we normalize the score of each feature within each 
patient to be between 0 and 1 by dividing the score by a sum over the scores of all the features. Then, the normal-
ized scores from each patient are added together to produce an aggregated score showing contribution from each 
feature. Figure 4 shows the contribution from each MRI sequence and PI. It is clear that PI contributes the most.
Conclusion
Despite the vast amounts of data being collected for individual patients, the promise of personalized medicine still 
remains to be fully realized. Data driven, machine learning processes provide a way to harness more and more of 
the incoming data. However, in the case of cancer, this avalanche of data still only represents limited snapshots of 
small regions of a complex, heterogeneous, and adapting system. Thus, machine learning models continue to be 
highly susceptible to overfitting and are notorious for not yielding reproducible results37–39. Mechanistic models 
can help guide machine learning models by providing information regarding the overarching principles guiding 
the system. This paper represents a key broad first step in demonstrating how combining these methodologies to 
achieve better results can be done.
In this paper, we have proposed a hybrid model leveraging principles from both machine learning and mechanis-
tic models, the ML-PI model. This model aims to provide patient-specific spatial maps of tumor cell density within 
a given GBM patients’ brain for enhanced surgical and radiation therapy planning. This hybrid model leverages 
multiparametric MRI and PI tumor cell density predictions under a graph-based SSL framework. Both parameter 
tuning methods for the ML-PI model, patient-specific and uniform, were able to outperform the PI model alone and 
the ML model alone. Of note, the patient-specific tuning statistically significantly outperformed the other models, 
achieving a MAPE score of 0.1 and a correlation coefficient of 0.84 between predicted and true values. The impor-
tance of the hybrid paradigm was further emphasized through our Relief-ML-PI algorithm, which revealed that the 
PI tumor cell density prediction contributed most significantly to the prediction of all the included image features.
There are certainly limitations to the results presented in this paper. First and foremost, while the dataset is 
novel, it is small and only includes primary GBM patients. Thus, a leave-one-patient out framework was used as 
an initial validation check, but more data is certainly needed to supply a richer training and testing ground for 
this model and to explore the applicability of our model in the recurrent setting. Second, our model depends on 
six distinct MRI sequences, which are not all standardly acquired and some of which, e.g. perfusion, are known to 
vary significantly from institute to institute. Thus, the GBM patient population for which our model can be imme-
diately utilized is limited. In future studies, we intend to study the decrease in accuracy as sequence requirements 
are removed in hopes of identifying a model that can be more broadly deployed. Third, the best accuracy was 
achieved for the patient-specific ML-PI, which does require a patient to already have had a biopsy in order for the 
prediction to be made. This certainly limits its ability to aid in surgical planning, but does not impact its potential 
usefulness in sculpting the dose map for radiation therapy. Further, we note that while the uniform model was not 
as accurate, it still outperformed the PI and ML models alone and could provide an initial prediction for an active 
sampling method to guide surgeons during surgery.
Parameter allowed to be patient-specific
γA γI η
MAPE ± SD 0.127 ± 0.129 0.156 ± 0.154 0.140 ± 0.153
Pearson correlation 0.792 0.676 0.713
Table 2. Prediction accuracy of ML-PI with partially-uniform tuning.
Figure 4. Contributions of PI and MRI sequences to ML-PI cell density prediction.
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It is well accepted that GBM tumor cells exist beyond the enhancement observed on T1Gd MRI, the main sur-
gical target. Radiation dose plans, implemented after surgery, try to account for this with broad margins of high 
dose out 2 cm from the enhancement and lower doses up to 4 cm away. Unfortunately, GBMs uniformly recur 
and the location of recurrence is almost always within the field of high dose radiation treatment. We believe the 
continued failure of radiation therapy is a direct result of the fact that standard-of-care dose plans and shapes are 
driven to be simultaneously aggressive and conservative. They are aggressive in wide margins by the knowledge 
that the cells are, but then are conservative in dose delivered due to the uncertainty in their precise location and 
the desire to preserve normal brain. We believe that as our model continues to be refined and is hopefully shown 
to be reliable, it can be used to better inform dose plans to be precisely aggressive and precisely conservative.
We are continuing to accrue patients from multiple institutions to our study to increase our dataset both in 
size and diversity. Future work will encompass retraining and testing our models with these new datasets and 
investigating possible other critical information that may produce more accurate models such as patient sex or 
tumor location. Should our model prove reliable, it will help localize invasive tumor populations within the oth-
erwise non-specific T2W regions to better inform resection and radiation therapy, potentially increasing overall 
survival for GBM patients.
Data Availability
The datasets generated during and/or analyzed during the current study are not publicly available due to institu-
tional review board requirements but are available from the corresponding author on reasonable request.
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